Heart Test Laboratories I... (HSCS)
Heart Test Laboratories Statistics
Share Statistics
Heart Test Laboratories has 1.04M shares outstanding. The number of shares has increased by -98.5% in one year.
| Shares Outstanding | 1.04M |
| Shares Change (YoY) | -98.5% |
| Shares Change (QoQ) | 7.34% |
| Owned by Institutions (%) | 2.89% |
| Shares Floating | 933.58K |
| Failed to Deliver (FTD) Shares | 3.22K |
| FTD / Avg. Volume | 9.51% |
Short Selling Information
The latest short interest is 54.95K, so 5.61% of the outstanding shares have been sold short.
| Short Interest | 54.95K |
| Short % of Shares Out | 5.61% |
| Short % of Float | 6.22% |
| Short Ratio (days to cover) | 2.41 |
Valuation Ratios
The PE ratio is -0.49 and the forward PE ratio is -0.49. Heart Test Laboratories's PEG ratio is 0.
| PE Ratio | -0.49 |
| Forward PE | -0.49 |
| PS Ratio | 175.12 |
| Forward PS | 0.6 |
| PB Ratio | 0.45 |
| P/FCF Ratio | -0.53 |
| PEG Ratio | 0 |
Enterprise Valuation
Heart Test Laboratories Inc. has an Enterprise Value (EV) of 6.62M.
| EV / Earnings | -1 |
| EV / Sales | 356.11 |
| EV / EBITDA | -1.08 |
| EV / EBIT | -1.05 |
| EV / FCF | -1.07 |
Financial Position
The company has a current ratio of 4.2, with a Debt / Equity ratio of 0.14.
| Current Ratio | 4.2 |
| Quick Ratio | 3.84 |
| Debt / Equity | 0.14 |
| Total Debt / Capitalization | 12.41 |
| Cash Flow / Debt | -5.86 |
| Interest Coverage | -17.81 |
Financial Efficiency
Return on equity (ROE) is -0.9% and return on capital (ROIC) is -75.49%.
| Return on Equity (ROE) | -0.9% |
| Return on Assets (ROA) | -0.7% |
| Return on Capital (ROIC) | -75.49% |
| Revenue Per Employee | $1,240 |
| Profits Per Employee | $-440,347.2 |
| Employee Count | 15 |
| Asset Turnover | 0 |
| Inventory Turnover | 0.01 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -74.45% in the last 52 weeks. The beta is 2.9, so Heart Test Laboratories's price volatility has been higher than the market average.
| Beta | 2.9 |
| 52-Week Price Change | -74.45% |
| 50-Day Moving Average | 3.57 |
| 200-Day Moving Average | 3.93 |
| Relative Strength Index (RSI) | 43.02 |
| Average Volume (20 Days) | 33.91K |
Income Statement
In the last 12 months, Heart Test Laboratories had revenue of 18.6K and earned -6.61M in profits. Earnings per share was -18.74.
| Revenue | 18.6K |
| Gross Profit | 12.52K |
| Operating Income | -6.31M |
| Net Income | -6.61M |
| EBITDA | -6.16M |
| EBIT | -6.31M |
| Earnings Per Share (EPS) | -18.74 |
Balance Sheet
The company has 5.81M in cash and 1.04M in debt, giving a net cash position of 4.77M.
| Cash & Cash Equivalents | 5.81M |
| Total Debt | 1.04M |
| Net Cash | 4.77M |
| Retained Earnings | -67.36M |
| Total Assets | 7.78M |
| Working Capital | 2.39B |
Cash Flow
In the last 12 months, operating cash flow was -6.07M and capital expenditures -125.27K, giving a free cash flow of -6.2M.
| Operating Cash Flow | -6.07M |
| Capital Expenditures | -125.27K |
| Free Cash Flow | -6.2M |
| FCF Per Share | -17.57 |
Margins
Gross margin is 67.31%, with operating and profit margins of -33.9K% and -35.51K%.
| Gross Margin | 67.31% |
| Operating Margin | -33.9K% |
| Pretax Margin | -35.51K% |
| Profit Margin | -35.51K% |
| EBITDA Margin | -33.1K% |
| EBIT Margin | -33.9K% |
| FCF Margin | -33.31K% |
Dividends & Yields
HSCS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -554.44% |
| FCF Yield | -176.87% |
Analyst Forecast
The average price target for HSCS is $13.5, which is 299.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $13.5 |
| Price Target Difference | 299.4% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on May 17, 2024. It was a backward split with a ratio of 1:100.
| Last Split Date | May 17, 2024 |
| Split Type | backward |
| Split Ratio | 1:100 |
Scores
| Altman Z-Score | -12504.69 |
| Piotroski F-Score | 1 |